Protara Therapeutics, Inc. (NASDAQ:TARA) Receives $20.40 Consensus PT from Brokerages
Shares of Protara Therapeutics, Inc. (NASDAQ:TARA – Get Free Report) have received an average rating of “Buy” from the six ratings firms that are presently covering the firm, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average 12-month price target among analysts that have issued a report on the […]
Shares of Protara Therapeutics, Inc. (NASDAQ:TARA – Get Free Report) have received an average rating of “Buy” from the six ratings firms that are presently covering the firm, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average 12-month price target among analysts that have issued a report on the […]
